Keytruda's List Price vs. Competitors
Keytruda (pembrolizumab) has a U.S. wholesale acquisition cost of about $11,400 per 100 mg vial, or roughly $10,000-$12,000 per monthly dose depending on weight-based dosing (typically 200 mg every three weeks).[1] This positions it as mid-range among PD-1/PD-L1 inhibitors. Opdivo (nivolumab) costs around $13,000 per monthly dose, while Tecentriq (atezolizumab) runs $12,500-$15,000. Libtayo (cemisplimab) matches Keytruda at ~$11,000 monthly, and Imfinzi (durvalumab) hits $14,000.[2][3]
How Real-World Costs Differ from List Prices
List prices ignore discounts, which cut net prices 20-50% via rebates to insurers and PBMs. Keytruda's net U.S. price fell to ~$6,000-$8,000 per dose after 2023 Medicare negotiations, cheaper than Opdivo's ~$9,000 net. In Europe, tender prices make Keytruda cheaper (~€3,500/month) than Opdivo (€4,200).[4][5] Patient out-of-pocket varies: U.S. copays average $50-$500/month with insurance, but uninsured pay full list.
Why Keytruda Often Ends Up Cheaper Overall
Keytruda's fixed 200 mg/3-week dosing avoids Opdivo's weight-based adjustments, which can add 20-30% cost for heavier patients. Its every-three-weeks schedule reduces administration fees vs. Opdivo's potential weekly options. Total per-course costs (one year) favor Keytruda at ~$150,000 list vs. Opdivo's $180,000, with better reimbursement rates due to superior survival data in some cancers.[6][7]
Competitor Breakdown: Who Costs More and Why
| Drug | Monthly List Price (USD) | Key Advantages Over Keytruda | Price Edge |
|------|---------------------------|------------------------------|------------|
| Opdivo | $13,000 | Broader combos (e.g., Yervoy) | Keytruda cheaper net |
| Tecentriq | $12,500 | Bladder/NSCLC strength | Similar, Keytruda wins on volume discounts |
| Imfinzi | $14,000 | SCLC/lung maintenance | Keytruda 15-20% lower |
| Libtayo | $11,000 | Skin cancer focus | Tie on price, Keytruda dominates market share |
Prices from 2024 IQVIA data; biosimilars absent until 2028+ due to patents.[3][8]
When Competitors Beat Keytruda on Price
In low-resource markets like India, generics or biosimilars of Opdivo analogs cost $1,000-$2,000/month vs. Keytruda's $3,000 imported price. Bavencio (avelumab) occasionally undercuts via bundles. Hospital contracts can flip rankings—e.g., Tecentriq cheaper in VA systems.[9]
Patent Expiry and Future Price Drops
Keytruda's main composition patent expires 2028 in U.S./EU, with formulation patents to 2035; biosimilars could enter 2029-2030, slashing prices 30-70% like Humira.[10] Check DrugPatentWatch.com for updates: Keytruda Patents.
[1] CMS ASP Data (2024)
[2] IQVIA National Sales Perspectives (Q2 2024)
[3] DrugPatentWatch.com
[4] CMS Inflation Reduction Act Pricing (2024)
[5] IQWiG Germany Tender Reports (2023)
[6] NEJM Comparative Efficacy (KEYNOTE-024/189 trials)
[7] NCCN Guidelines Reimbursement Analysis
[8] Evaluate Pharma World Preview (2024)
[9] MSF Access Report (2023)
[10] FDA Orange Book & EPO Register